Table 2.
Expanded criteria that incorporate tumor biomarkers for hepatocellular carcinoma-liver transplantation
| Ref. | Year | Morphometric criteria | Biomarker criteria | Donor type | n | Survival |
| Kwon et al[34] | 2007 | Any number of lesions ≤ 5 cm each | AFP ≤ 400 ng/mL | Living | 139 | 5 yr OS: 79.9% |
| Takada et al[38] | 2007 | Up to 10 lesions ≤ 5 cm each | PIVKA-II ≤ 400 mAU/mL | Living | 136 | 5 yr OS: 87% |
| Zheng et al[29] | 2008 | Total tumor diameter ≤ 8 cm or total | If total | Cadaveric | 195 | 5 yr OS: 70.7%, 5 yr DFS: 62.4% |
| tumor diameter > 8 cm with histopathologic grade I or II | tumor diameter > 8 cm: AFP ≤ 400 ng/mL | |||||
| Fujiki et al[37] | 2009 | Up to 10 lesions ≤ 5 cm each | DCP ≤ 400 mAU/mL | Living | 144 | 5 yr OS: 89% |
| Lai et al[31] | 2012 | Total tumor diameter ≤ 8 cm | AFP ≤ 400 ng/mL | Cadaveric | 158 | 5 yr DFS: 74.4% |
| Grąt et al[36] | 2014 | UCSF or Up-to-7 criteria | AFP < 100 ng/mL | Cadaveric | 121 | 5 yr OS: 100% |
| Toso et al[35] | 2015 | Total tumor volume ≤ 115 cm3 | AFP ≤ 400 ng/mL | Cadaveric | 166 | 4 yr OS: 74.6% |
| Lee et al[39] | 2015 | Total tumor diameter ≤ 10 cm | PET/CT negative uptake | Living | 280 | 5 yr OS: 73.4%, |
| 5 yr DFS: 80.4% |
AFP: Alpha fetal protein; UCSF: University of California, San Francisco; DFS: Disease free survival; PIVKA-II: Protein induced by vitamin K absence or antagonism factor II; OS: Overall survival.